Literature DB >> 33762374

Ulcerative colitis: an update.

Jonathan P Segal1, Jean-Frédéric LeBlanc2, Ailsa L Hart3.   

Abstract

Ulcerative colitis is a relapsing and remitting disease that is increasing in incidence and prevalence. Management aims to achieve rapid resolution of symptoms, mucosal healing and improvement in a patient's quality of life. 5-aminosalicylate acid medications remain the first-line treatment for mild to moderate disease. In the event of suboptimal response to these medications, escalation to immunosuppressive medications and biologics may be necessary. Importantly, despite best medical therapy, surgery may be required in a proportion of patients. The future will likely see an array of new therapeutic options for those with ulcerative colitis with the potential for a more personalised treatment approach. © Royal College of Physicians 2021. All rights reserved.

Entities:  

Keywords:  biologics; inflammatory bowel disease; ulcerative colitis

Mesh:

Year:  2021        PMID: 33762374      PMCID: PMC8002778          DOI: 10.7861/clinmed.2021-0080

Source DB:  PubMed          Journal:  Clin Med (Lond)        ISSN: 1470-2118            Impact factor:   2.659


  19 in total

1.  Reliability and initial validation of the ulcerative colitis endoscopic index of severity.

Authors:  Simon P L Travis; Dan Schnell; Piotr Krzeski; Maria T Abreu; Douglas G Altman; Jean-Frédéric Colombel; Brian G Feagan; Stephen B Hanauer; Gary R Lichtenstein; Philippe R Marteau; Walter Reinisch; Bruce E Sands; Bruce R Yacyshyn; Patrick Schnell; Christian A Bernhardt; Jean-Yves Mary; William J Sandborn
Journal:  Gastroenterology       Date:  2013-07-25       Impact factor: 22.682

2.  Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis.

Authors:  Bruce E Sands; William J Sandborn; Remo Panaccione; Christopher D O'Brien; Hongyan Zhang; Jewel Johanns; Omoniyi J Adedokun; Katherine Li; Laurent Peyrin-Biroulet; Gert Van Assche; Silvio Danese; Stephan Targan; Maria T Abreu; Tadakazu Hisamatsu; Philippe Szapary; Colleen Marano
Journal:  N Engl J Med       Date:  2019-09-26       Impact factor: 91.245

3.  New Drugs in the Ulcerative Colitis Pipeline: Prometheus Unbound.

Authors:  Silvio Danese
Journal:  Gastroenterology       Date:  2019-12-17       Impact factor: 22.682

4.  Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis.

Authors:  William J Sandborn; Chinyu Su; Bruce E Sands; Geert R D'Haens; Séverine Vermeire; Stefan Schreiber; Silvio Danese; Brian G Feagan; Walter Reinisch; Wojciech Niezychowski; Gary Friedman; Nervin Lawendy; Dahong Yu; Deborah Woodworth; Arnab Mukherjee; Haiying Zhang; Paul Healey; Julian Panés
Journal:  N Engl J Med       Date:  2017-05-04       Impact factor: 91.245

5.  Reappraising Risk Factors for Inflammatory Bowel Disease-associated Neoplasia: Implications for Colonoscopic Surveillance in IBD.

Authors:  Shailja C Shah; Steven H Itzkowitz
Journal:  J Crohns Colitis       Date:  2020-09-07       Impact factor: 9.071

6.  Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial.

Authors:  John G Williams; M Fasih Alam; Laith Alrubaiy; Ian Arnott; Clare Clement; David Cohen; John N Gordon; A Barney Hawthorne; Mike Hilton; Hayley A Hutchings; Aida U Jawhari; Mirella Longo; John Mansfield; Jayne M Morgan; Frances Rapport; Anne C Seagrove; Shaji Sebastian; Ian Shaw; Simon P L Travis; Alan Watkins
Journal:  Lancet Gastroenterol Hepatol       Date:  2016-09

7.  Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme.

Authors:  William J Sandborn; Julian Panés; Bruce E Sands; Walter Reinisch; Chinyu Su; Nervin Lawendy; Nana Koram; Haiyun Fan; Thomas V Jones; Irene Modesto; Daniel Quirk; Silvio Danese
Journal:  Aliment Pharmacol Ther       Date:  2019-10-09       Impact factor: 8.171

8.  IBD prevalence in Lothian, Scotland, derived by capture-recapture methodology.

Authors:  Gareth-Rhys Jones; Mathew Lyons; Nikolas Plevris; Philip W Jenkinson; Cathy Bisset; Christopher Burgess; Shahida Din; James Fulforth; Paul Henderson; Gwo-Tzer Ho; Kathryn Kirkwood; Colin Noble; Alan G Shand; David C Wilson; Ian Dr Arnott; Charlie W Lees
Journal:  Gut       Date:  2019-07-11       Impact factor: 31.793

9.  Incidence and prevalence of inflammatory bowel disease in UK primary care: a population-based cohort study.

Authors:  Thomas Joshua Pasvol; Laura Horsfall; Stuart Bloom; Anthony Walter Segal; Caroline Sabin; Nigel Field; Greta Rait
Journal:  BMJ Open       Date:  2020-07-19       Impact factor: 2.692

10.  Long-term safety of vedolizumab for inflammatory bowel disease.

Authors:  Edward V Loftus; Brian G Feagan; Remo Panaccione; Jean-Frédéric Colombel; William J Sandborn; Bruce E Sands; Silvio Danese; Geert D'Haens; David T Rubin; Ira Shafran; Andrejus Parfionovas; Raquel Rogers; Richard A Lirio; Séverine Vermeire
Journal:  Aliment Pharmacol Ther       Date:  2020-09-02       Impact factor: 8.171

View more
  5 in total

1.  [E.faecium QH06 alleviates TNBS-induced colonic mucosal injury in rats].

Authors:  K Kuerbannaimu; J Zhao; A Mukaidaisi; H Wang; J Zhu; W Pan; A Kasimujiang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2022-07-20

2.  Cell division control 42 elevates during infliximab therapy, and its increment relates to treatment response in ulcerative colitis patients.

Authors:  Lin Liu; Qinger Liu; Jian Chang; Xiaoxia Dong; Weiping Ma
Journal:  J Clin Lab Anal       Date:  2022-05-09       Impact factor: 3.124

Review 3.  Application of chitosan/alginate nanoparticle in oral drug delivery systems: prospects and challenges.

Authors:  Shangyong Li; Hui Zhang; Kaiwei Chen; Mengfei Jin; Son Hai Vu; Samil Jung; Ningning He; Zhou Zheng; Myeong-Sok Lee
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.419

4.  Endometrial Regenerative Cell-Derived Exosomes Attenuate Experimental Colitis through Downregulation of Intestine Ferroptosis.

Authors:  Yanglin Zhu; Hong Qin; Chenglu Sun; Bo Shao; Guangming Li; Yafei Qin; Dejun Kong; Shaohua Ren; Hongda Wang; Zhaobo Wang; Jingyi Zhang; Hao Wang
Journal:  Stem Cells Int       Date:  2022-08-22       Impact factor: 5.131

5.  Global trends in intestinal flora and ulcerative colitis research during the past 10 years: A bibliometric analysis.

Authors:  Lu Zhang; Shuai Xiong; Fengchen Jin; Fan Zhou; Hongjun Zhou; Jinhong Guo; Chuanbiao Wen; Biao Huang
Journal:  Front Microbiol       Date:  2022-09-07       Impact factor: 6.064

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.